Sagimet Biosciences Inc. Net Rentable Area
Sagimet Biosciences Inc. (SGMT) had Net Rentable Area of 7.20 thousand sqft as of 2026-05-28, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:NetRentableArea · last filed 2026-08-11
- 2026-05-28: Net Rentable Area 7.20K sqft.
- 2019-03-12: Net Rentable Area 3.03K sqft.
| Period end | Net Rentable Area |
|---|---|
| 2026-05-28 | 7.20K sqft 10-Q · filed 2026-08-11 |
| 2019-03-12 | 3.03K sqft 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |